Letters
Postmarketing surveillance does not catch all adverse events
BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7030.577 (Published 02 March 1996) Cite this as: BMJ 1996;312:577- Paul O'Brien
- Session clinical medical officer Raymede Clinic, London W10 5SH
EDITOR,—H B M Reijnen and W J Atsma, of Organon Pharmaceuticals, use data from the company's product surveillance database to show that the risk of venous thromboembolism with the pills Marvelon and Mercilon, both of which contain desogestrel, is highest in the first few months of use and falls dramatically thereafter.1 The World Health Organisation's …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.